

SEQUENCE LISTING

<110> Johnson & Johnson Research Pty Ltd  
 <120> A means of producing and utilising a population of disease  
 specific cytotoxic T lymphocytes  
 <130> 02 1355 7401  
 <160> 9  
 <170> PatentIn version 3.3

<210> 1  
 <211> 17  
 <212> RNA  
 <213> Human immunodeficiency virus type 1  
 <400> 1  
 ggagccagua gauccua 17

<210> 2  
 <211> 17  
 <212> RNA  
 <213> Human immunodeficiency virus type 1  
 <400> 2  
 ggagccagua gauccua 17

<210> 3  
 <211> 38  
 <212> DNA  
 <213> Artificial  
 <220>  
 <223> Rz2 ribozyme sequence  
 <400> 3  
 ttaggatcct gatgagtccg tgaggacgaa actggctc 38

<210> 4  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens  
 <400> 4

Ile Leu Lys Glu Pro Val His Gly Val

1 5

<210> 5

<211> 9

<212> PRT

<213> Homo sapiens

<400> 5

Ser Leu Tyr Asn Thr Val Ala Thr Leu

1 5

<210> 6

<211> 12

<212> PRT

<213> Artificial

<220>

<223> CD8 peptide

<400> 6

Ala Ala Glu Gly Leu Asp Thr Gln Arg Phe Ser Gly

1 5 10

<210> 7

<211> 41

<212> DNA

<213> Artificial

<220>

<223> Sub G5-FD

<220>

<221> misc\_binding

<222> (15)..(15)

<223> FAM moiety attached

<220>

<221> misc\_binding

<222> (24)..(24)

<223> DABCYL moiety attached

<400> 7

caccaaaaga gaactgcaat guttcaggac ccacaggagc g 41

<210> 8

<211> 21

<212> DNA

<213> Artificial

<220>

<223> 5L1A primer

<400> 8

gagttctacc ggcagtgcaa a 21

<210> 9

<211> 76

<212> DNA

<213> Artificial

<220>

<223> 3L1Dz5 primer

<400> 9

caccaaaaga gaactgcaat tcgttgtagc tagcctttca ggacccacag gagcggcaag 60

caattcggtc tgtatc 76